In eukaryotic cells, the genome is spatially organized in a non-random fashion within the confines of 36 the interphase nucleus, and most genes occupy preferred nuclear positions.
Introduction
clinically useful, our findings of subtype-specific gene positioning patterns in prostate cancer 152 provides additional evidence for the potential of spatial genome organization as a novel prognostic 153 biomarker. 154 155 156
Materials and Methods 157
Tissue Fluorescence in situ Hybridization (FISH) 158 4-5µm thick normal, benign disease (hyperplasia and chronic prostatitis), and cancerous formalin-159 fixed, paraffin embedded (FFPE) human prostate tissues were obtained from US Biomax Inc, 160
Imgenex Corporation, BioChain Institute, or the University of Washington (Prof. Lawrence True) 161 under the guidelines and approval of the Institutional Review Board of the University of Washington 162 (#00-3449) ( Supplementary Table 1 ). Patient tissues were de-identified before receipt. 163 164
To generate probe DNA for FISH, bacterial artificial chromosome (BAC) clones were labeled with 165 biotin-(Roche), digoxigenin-(Roche) or DY-547P1-(Dyomics GmbH) conjugated dUTPs by nick 166 translation (Meaburn, 2010) . The following BACs were used: RP11-727M18 (to position SP100, 167 chromosome location: 2q37.1); RP11-270M14 (TGFB3, 14q24.3); RP11-1021J5 (SATB1, 3p24.3); 168 RP11-35P22 (LMNA, 1q22) (BACPAC resource center). Single-or dual-probe FISH experiments 169 were performed as previously described (Meaburn et al., 2009; Leshner et al., 2016; Meaburn et al., 170 2016), with the following modifications: for most tissues a 1 hour 60ºC bake step was performed, 171
prior to the xylenes (Macron Fine Chemicals) deparaffinization step; 40µg yeast RNA (Life 172
Technologies) was used in place of tRNA; DyLight 488 labeled anti-digoxigenin (Vector 173
Laboratories) was occasionally used to detect digoxigenin-labeled probe DNA; and no probe 174 detection steps were required for the fluorescently labeled DY-547P1-dUTP FISH probes. 175 176
Image Acquisition 177
Epithelial nuclei were randomly imaged throughout the tissue, unless benign and malignant glands 178
were present in the same tissue section. In such cases, care was taken to image and analyze the 179 different morphologies separately, whilst still acquiring epithelial cell nuclei randomly within the 180 benign or malignant regions to capture as much diversity within the cancer (or benign tissue) as 181 possible. Image accusation was performed as previously described, using an IX70 (Olympus) 182
Deltavision (Applied Precision) system, with a 60x 1.42N oil objective lens (Olympus), an auxiliary 183 magnification of 1.6, and a X-Y pixel size of 67.25nm (Meaburn et al., 2009; Leshner et al., 184 2016; Meaburn et al., 2016) or with a similar imaging regime using an IX71 (Olympus) Deltavision 185 (Applied Precision) system, 100x 1.40N oil objective lens (Olympus), with an X-Y pixel size of 186 64.6nm. Image stacks were acquired to cover the thickness of the tissue section, with a 0.5µm or 187 0.25µm step interval along the Z axis, respectively. All image stacks were deconvolved and 188 converted to maximum intensity projections using SoftWoRx (Applied Precision). The change in 189 acquisition approach did not affect the resulting positioning data from the image datasets. We 190 obtained similarly statistically identical distributions for the position of a gene in a given tissue using 191 the two different acquisition methods (P = 0.79-0.86, Kolmogorov-Smirnov (KS) test), as from 192 repeat analysis of tissues using an identical acquisition method (P = 0.65-0.99 (Meaburn et al., 2009), 193 unpublished data). 194 195
Image Analysis 196 Image analysis to determine the radial position of a gene within a tissue was performed as previously 197
described (Meaburn et al., 2009; Leshner et al., 2016; Meaburn et al., 2016) . Briefly, 96-167 198 interphase epithelial nuclei were manually segmented in Photoshop (Adobe) for each gene in each 199 tissue, except for TGFB3 in tissue C10 where 88 nuclei were segmented. To map the radial position 200 This is a provisional file, not the final typeset article of the gene loci, nuclei were run though custom image analysis software scripts, using MATLAB 201 (The Mathsworks Inc.), with DIPImage and PRTools toolboxes (Deft University, P. Gudla and S 202 Lockett (NCI/NIH); (Meaburn et al., 2009) ). Euclidean distance transform (EDT) was computed for 203 each nucleus, to assign every pixel within the nucleus its distance to the nearest nuclear boundary. 204
The software then determined the nuclear EDT position of the geometric gravity center of the 205 automatically detected FISH signals. To normalize for variations in nuclear size and shape between 206 specimens, the EDT of a FISH signal was normalized to the maximal nuclear EDT for that nucleus, 207 with 0 denoting the nuclear periphery and 1 the nuclear center. The normalized FISH signal EDTs for 208 a given gene in each specimen was then combined to produce a relative radial distribution (RRD), 209
and a cumulative frequency distribution was generated. All detected alleles in a nucleus were 210
included, regardless of the number present. In the case of the pooled normal distributions (PNDs), the 211 normalized FISH EDTs from all allele in all the normal tissues analyzed, for a given gene, were 212 combined into a single dataset ( Supplementary Figure 1) . To determine whether the positioning patterns of these genes were able to stratify prostate cancers 247 into clinically relevant subgroups, we performed FISH on a panel of 4-5µm thick FFPE human 248 prostate tissues, which included a diverse group of 32 prostate cancer specimens covering a range of 249 Gleason scores and T stages, with and without known metastases, and 25 benign prostate tissues (for 250 details see Supplementary Table 1 ). To map the spatial positioning pattern of a gene in a given tissue, 251
we measured the radial position, normalized for nuclear size and shape, of each locus in ~120 252 epithelial interphase nuclei as previously described (see Materials Figure 1 ). 258 259 We initially assessed the repositioning rates for the candidate genes in the assorted set of prostate 260 cancer samples. Compared to the PND, SP100 was in a statistically significantly different radial 261 position in 44.4% (12/27) prostate cancer specimens ( Figure 1 , Table 1 , Supplementary Table 2 ). 262
Similarly, LMNA repositioned in 36.4% (4/11), SATB1 in 34.8% (8/23), and TGFB3 in 31.8% (7/22) 263 of prostate cancer tissues ( Figure 1 , likelihood of a gene repositioning in a cancer did not correlated with gene copy number ( Figure 1 , 269
Supplementary Table 6 ). 270 271
In addition to whether a gene was repositioned, the direction of its repositioning was also determined 272 ( Figure 1 , Table 1 ). Of the 12 prostate cancers in which SP100 was repositioned, the gene was more 273
internally positioned compare to the PND in five cancer tissues (5/12; 41.7%) and more peripherally 274 positioned in seven (58.3%). Similarly, TGFB3 was more internally positioned in three (3/7; 42.9%) 275
cancers and more peripherally positioned in four (57.1%). SATB1 was more internally positioned in 276
five of the eight cancers where the gene was repositioned (62.5%) and more peripherally positioned 277 in three cancers (37.5%). Conversely, LMNA repositioned to a more internal nuclear location in all 278 four cancer specimens in which the gene was repositioned ( Figure 1 , Table 1 ). The direction of 279
repositioning accounted for most of the differences in the positioning patterns for a given gene 280 between the cancer tissues in which repositioning occurred. There was little variation between the 281
RRDs of a gene between the cancers in which the gene was more internally positioned. Similarly, 282
there was little statistical variation in RRDs among cancers in which the gene was more peripherally 283 positioned, with the exception of SATB1 ( In contrast, the behavior of a gene in a cancerous tissue compared to the PND was a better indicator 300 to detect differential positioning between subgroups (Figure 1 , Supplementary Figure 2 , Tables 1, 3  301 and 4, Supplementary Tables 2-5 ). We first compared positioning patterns to Gleason score. In line 302
with the clinical risk assessment of prostate cancers (Thompson et al., 2007), we classified Gleason  303 scores of 2-6 as a low Gleason score, Gleason score 7 as intermediate, and scores of 8-10 as a high 304
Gleason score. There was a modest increase in the proportion of cancer specimens with either SATB1 305 or LMNA repositioned, compared to the PND, with increasing Gleason score, however, in the case of 306
LMNA this may be due to the small sample size (Table 3) . SATB1 was in a statistically different 307 nuclear position in 25% (2/8) of low Gleason score cancers, 33.3% (3/9) Gleason score 7 cancers and 308 50% (3/6) high Gleason score cancers. Similarly, LMNA repositioned in 33.3% of low (2/6) and 309 intermediate (1/3) Gleason score cancers, and 50% (1/2) of high Gleason score cancers. Inclusion of 310 the direction of repositioning did little to aid stratification (Table 3) . Thus, we concluded that neither 311 SATB1 nor LMNA are biomarkers of Gleason score. The proportion of cancers in which SP100 and 312
TGFB3 repositioned also did not stratify Gleason score groups. SP100 was slightly more frequently 313
repositioned in low Gleason score cancers specimens, repositioning in 54.5% ( with Gleason score ( Supplementary Figure 2A , Table 4 ). Both SP100 and TGFB3 shifted to a more 319 peripheral position in 100% of the low Gleason score cancers in which these genes showed altered 320 radial position. In contrast, SP100 and TGFB3 were in a more internal position in 83.3% (5/6) and 321 75.0% (3/4), respectively, of the Gleason score 7 and higher cancers in which they repositioned. 322
Intermediate/high Gleason score cancer tissue repositioning is not exclusively more internal, since for 323 both genes a more peripheral positioning was detected in a Gleason score 9 prostate cancer 324 ( Supplementary Figure 2A , Tables 1 and 4 ). The positioning patterns of SP100 and TGFB3 could not 325 distinguish intermediate Gleason score cancer tissues from high Gleason score cancer tissues 326
( Supplementary Figure 2A , Tables 1 and 4).  327  328 We also assessed if positioning patterns correlated with Gleason grade. For all four genes, increasing 329
Gleason grade did not correlate with the percentage of cancer specimens in which the genes 330
repositioned (Tables 3 and 4 ). Consistent with Gleason score, the direction that SATB1 and LMNA 331 repositioned did not aid in stratifying cancers by Gleason grade (Table 3) , but the direction of 332
repositioning did correlate with Gleason grade for SP100 and TGFB3 (Table 4 ). As with Gleason 333 score, in the more highly differentiated cancers (Gleason grades 1-3) SP100 and TGFB3 repositioned 334 towards the nuclear periphery in 100% (5 and 3 cancers, respectively) of the cancers in which these 335 genes repositioned. Yet, in the poorly differentiated cancers (Gleason grade 4 and 5) both genes 336 preferentially repositioned towards the nuclear interior. SP100 was more internally positioned in 80% 337
(4/5) of Gleason grade 4 and 5 cancer in which SP100 repositioned and TGFB3 was more internally 338 positioned in 66.7% (2/3) of the Gleason grade 4 and 5 cancers in which TGFB3 was repositioned, 339 compared to the PND (Table 4 ). The similarity between Gleason grade and Gleason score positioning 340 patterns are not surprising given that Gleason score is the sum of the two most prominent Gleason 341 grades (Epstein et al., 2005; Epstein, 2018 ). An important caveat to be noted is that while the 342 subgrouping of the cancers was based on the most predominant Gleason grade of the tissue, it is not 343 necessarily the predominant Gleason grade of the nuclei analysis from each specimen. 344 345
Collectively, these observations demonstrate that while positioning patterns performed less well than 346
the Gleason system at stratifying cancers, we identify differential gene positioning patterns between 347 subgroups of prostate cancers. 348 349
Multiplexing SP100 and TGFB3 Improves Detecting Intermediate and High Gleason Score 350
Cancers 351
Although both SP100 and TGFB3 displayed differential positioning patterns between low and 352 intermediate/high Gleason score cancer specimens, the sensitivity for subgrouping prostate cancers 353
by Gleason score based on positioning patterns is low. Using a more peripheral positioning of SP100 354 compared to the PND as a marker of low Gleason score cancers, the false negative rate (percentage 355 of cancers without a more peripheral positioning) is 45.4% (5/11 low Gleason score cancers; Table  356 1). For TGFB3 the false negative rate is even higher at 70% (7/10; improve the sensitivity, SP100 and TGFB3 would need to be frequently repositioned in different 370 cancer specimens. Of a subset of 19 cancer tissues in which both genes were positioned, 10 (52.6%) 371
had differential repositioning patterns for SP100 to that of TGFB3 (Table 1 , Supplementary Table 7 ). 372
For six of these cancers SP100 was repositioned but TGFB3 was not, whereas in three cancers only 373
TGFB3 was repositioned. For one cancer sample, both genes were repositioned, compared to their 374
PND, but they relocated in opposite directions, with SP100 being more peripherally positioned, while 375
TGFB3 was more internally positioned (Table 1 , Supplementary Table 7 ). However, multiplexing the 376 two genes did not improve the sensitivity to detect low Gleason score cancers above using SP100 377 alone. SP100 was more peripherally positioned in all five cancers where at least one of the two genes 378
repositioned (Table 1 , Supplementary Table 7 ). Nevertheless, multiplexing increased the sensitivity 379 of detecting intermediate/high Gleason score cancers (Table 1 , Supplementary Table 7 ). At least one 380 gene repositioned in eight of the 11 (72.7%) Gleason score 7 and higher cancers. Both SP100 and 381 TGFB3 contributed to the increased proportion of cancer specimens with repositioning events. Of the 382 seven cancers with only one of the two genes more internally repositioned, SP100 was more 383
internally repositioned in four and TGFB3 more internally positioned in three cancers (Table 1,  384  Supplementary Table 7 ). Using a more internal position of at least one of SP100 or TGFB3 the false 385 negative rate for detecting intermediate or high Gleason score cancers was reduced to 36.4% (4/11). 386
While most of the repositioning events in intermediate/high Gleason score cancers were to a more 387
internal position, in one cancer the only repositioning event resulted in a more peripheral location of 388 TGFB3 and in another cancer tissue, there was both a more peripheral and more internal 389
repositioning events, with SP100 more peripherally position and TGFB3 more internally located 390 (Table 1 , Supplementary Table 7 ). 391 392
Gleason score is not a perfect measure of risk. Given the variability in positioning patterns within the 393 same Gleason group, we asked if the positioning patterns could be useful to distinguish aggressive 394 This is a provisional file, not the final typeset article low Gleason core cancers from non-aggressive low Gleason score cancers. Such a marker would aid 395 treatment decisions. However, SP100 and TGFB3 were repositioned in a similar proportion of low 396
Gleason score cancers with or without metastasis (Table 1) . SP100 repositioned in 50% (2/4) of low 397
Gleason score cancers that had metastasized and 57.1% (4/7) of low Gleason score cancers without 398 metastases. Likewise, TGFB3 repositioned in 33.3% (1/3) of metastatic low Gleason score cancer 399 specimens and 28.8% (2/7) of non-metastatic low Gleason score cancer specimens (Table 1) Given the fact that low Gleason score cancers are fairly well differentiated tissues, it is possible that 408
low Gleason score cancers have a similar genome organization to benign disease. We therefore 409 sought to determine the cancer-specificity of the repositioning events. We positioned SP100, TGFB3, 410 SATB1 and LMNA in non-cancerous prostate tissues (Figure 2 , Supplementary Figure 1 , Tables 5 and  411 6, Supplementary Tables 2-5) . For all four genes we found that the positioning patterns were highly 412 similar between benign tissues. For SP100, TGFB3 and SATB1, only 9.1%-14.1% of comparisons 413 between the individual non-cancerous tissues reached significance. There was a little more variability 414 between benign tissues for LMNA, where 25% of cross-comparisons between benign tissues were 415 significantly different ( Figure 2 , Table 2 , Supplementary Table 2 -5).There was also little 416
repositioning of the four genes in benign tissues when compared to the PND, with repositioning in 417 7.7%-16.7% of benign tissues, depending on the gene (Figure 2 , Tables 5 and 6 ). SP100 was 418
statistically similarly positioned in all seven normal tissues, compared to the PND, but was 419 significantly repositioned in 40% (2/5) of benign disease tissue (Figure 2 , Tables 5 and 6 ). However, 420
the positioning patterns of SP100 were distinct in benign disease and low Gleason score cancer, since 421
it was more internally localized in the two benign disease tissues, yet more peripherally located in 422 low Gleason score cancers (Tables 1 and 5 ). 423 424
Inclusion of the direction of repositioning in the analysis further confirmed the specificity of the 425 repositioning events to the different Gleason score subgroups. When using more peripheral 426
positioning, compared to the PND, as a marker of low Gleason score prostate cancer, the false 427 positive rate for SP100 is very low, at 3.6%, since it is more peripherally positioned in only one of 28 428 normal, benign disease and higher Gleason score cancer tissues (Tables 1 and 5) . Similarly, TGFB3 429 was repositioned in a single normal tissue (12.5%; 1/8) and in none of the benign disease tissues 430 (0/5), compared to the PND (Figure 2 , Tables 5 and 6 ). Unlike SP100, the direction TGFB3 431 reposition in the normal tissue was the same as in low Gleason score cancer. However, the false 432 positive rate for using a more peripheral positioning of TGFB3 was relatively low at 8%, because it 433 was more peripherally positioned in two of the 25 benign tissues and higher Gleason score cancers 434 (Tables 1 and 5 ). The false positive rate of using a more internal position of SP100 or TGFB3 to 435 detect intermediate/ high Gleason score cancers is also low, at 8.7% and 0%, respectively, since 436
SP100 was more internally repositioned in only two of the 23 benign tissues and low Gleason score 437 cancer specimens and TGFB3 was not more internally repositioned in these groups of tissues (N=23; 438 no cancer cells are detected in the regional lymph nodes, whereas N1 denotes that the cancer has 452 spread into the regional lymph nodes. For M0 cancers, no distant metastasis are detected, while 453 distant metastases, to non-regional lymph nodes or organs, have occurred in M1 cancers (Thompson  454  et al., 2007) . 455 456 Positioning patterns for SP100 and SATB1 were similar in low and high T stage cancer specimens 457 and could not be used to distinguish the different T stage group cancers from each other (Tables 3  458  and 4 ). TGFB3 and LMNA were both more frequently repositioned in low T stage cancers to that of 459 high T stage cancers, but with high false positive rates (Tables 3 and 4 (Table 3) . 479 480
Finally, as a more direct measure of the aggressiveness of a cancer we compared non-metastatic 481 cancers (N0M0) and metastatic (N1/M1) prostate cancers (Supplementary Figure 2B, Figure 2B , Table 3 ). As with SP100 490
and TGFB3 as markers of Gleason score, the false negative rate for using LMNA positioning as a 491 This is a provisional file, not the final typeset article marker of non-metastatic cancer was high at 42.9% (3/7), and the false positive rate is relatively low 492 at 8.3% (1/12) (Tables 1, 3 and 5).  493  494 Taken together, our data suggest that there are distinct spatial gene positioning patterns between 495 some subgroups of prostate cancers, although the false negative rates were generally high, limiting 496 their potential for clinical use. 497 498
Discussion 499
To reduce overtreatment in cancer patients that receive no benefit from medical intervention, there is 500 an urgent need for biomarkers that predict the aggressiveness of a cancer. Here, we assess the 501 feasibility of utilizing the spatial positioning patterns of genes in interphase nuclei for prognostic 502 purposes in prostate cancer. We find a differential enrichment of specific positioning patterns for 503 multiple genes between clinically relevant subgroups of prostate cancers. While the false positive 504 rates for prognostic evaluation are low, the false negative rates are generally high, limiting clinical 505 usefulness. Our results of subtype-specific genome organization patterns suggest that it should be 506 possible to find clinically valuable prognostic GPB by screening additional genes and combinations 507 of genes. 508 509
The spatial organization of the genome is altered in diseased cells, and at least some of the changes to 510 genomic spatial positioning patterns are disease-specific (Meaburn, 2016 , 2016) . We hypothesized that heterogeneity within a cancer type may reflect the 516 aggressiveness of a cancer and therefore be of prognostic value. Prognosis-related repositioning of 517 genomic regions in several types of cancer has previously been reported, with increased clustering of 518 telomeres linked to poorer patient outcomes (Mai, 2018) . For example, at the time of diagnosis 519 telomeres were more likely to cluster in Hodgkin lymphoma patients whose disease later relapsed or 520 progressed compared to patients who responded well to treatment (Knecht et al., 2012) . Currently, 521
Gleason score and the presence or absence of metastasis are key clinicopathological tumor features 522 for predicting the aggressiveness of a prostate cancer. We find that SP100 and TGFB3 occupy 523 alterative positions in low Gleason score cancers compared to higher Gleason scored cancers, and 524
that LMNA repositions more internally in many non-metastatic and low risk prostate cancers, but 525 infrequently reposition in high risk/aggressive cancers. 526 527
Our previous identification of diagnostic GPBs was based on the percentage of cancer specimens in 528 which a gene had an alternative radial position, compared to its distribution in normal tissues 529 (Meaburn, 2016 choices. However, because the positioning patterns of our genes could not separate aggressive, 540 metastatic low Gleason score cancers from non-metastatic low Gleason score cancers, they are 541 unlikely to aid the decision of whether to treat a cancer or not. In keeping with a differential spatial 542 genome organization in cancers above and below the treatment threshold, we previously found 543
MMP9 to reposition in 20% of low Gleason score cancers compared to 82% of intermediate/high 544 Gleason score cancers . Unlike SP100 and TGFB3, the direction MMP9 545 repositioned did not aid stratification , unpublished data). MMP9 was 546 positioned predominantly in Gleason score 6 and 7 prostate cancers, making it unclear how specific 547 these positioning patterns are more generally to the different Gleason scores subgroups. SP100, 548
TGFB3 and MMP9 each map to different chromosomes (HSA 2, 14 and 20, respectively) and 549 therefore represent independent repositioning events within the subgroups of different Gleason score 550 cancers. 551 552
In our analysis we find low false positive rates for distinguishing low from intermediate/high Gleason  553 score cancers. In keeping with previous studies ( and TGFB3 amongst normal tissues and between normal and benign disease tissues, highlighting that 556 the gene repositioning in cancer tissues were specific to cancer. Despite the fact that low Gleason 557 score cancers represents fairly well differentiated tissues there were distinct positioning patterns for 558 SP100 and TGFB3 between low Gleason score cancers and benign disease, which are considered 559 differentiated tissues. TGFB3 did not reposition in benign disease and SP100 was repositioned in 560 only 20% of the benign disease tissues. However, unlike low Gleason score cancers, SP100 was more 561
internally positioned in benign disease tissues, and therefore does not contribute to the false positive 562 rate when using more peripheral positioning of these genes to detect low Gleason score cancers. 563
Unlike biomarkers used to diagnose cancer, the false positive rate of detecting a subtype of cancer for 564 prognostic purposes is not only generated from non-cancerous tissues, it needs to also include 565 cancers from the alternative subgroups. Even so, the false positive rates of detecting low Gleason 566 score prostate cancers, were low because the direction of repositioning for SP100 and TGFB3 was 567 mostly specific to the subgroups. In contrast to the false positive rates, the false negative rates for 568 SP100 and TGFB3 were high, at 45-70%. We have previously found that for some genes 569 multiplexing reduces the false negative rate and thus the sensitivity of detecting cancer (Meaburn et 570 al., 2009; Leshner et al., 2016) . Constant with this, we find that multiplexing SP100 and TGFB3 571 reduces the false negative rate of detecting intermediate and higher Gleason score cancers. However, 572 multiplexing with a more peripheral position of either SP100 or TGFB3 did not reduce the false 573 negative rate for low Gleason score cancers from that of using SP100 alone. We conclude that the 574 observed high false negative rates reduce marker strength and the utility of these genes for prognostic 575 purposes. 576 577
Even though the positioning patterns of SP100 and TGFB3 are inferior to the Gleason system at 578 stratifying cancers, our results reveal subtype-specific genome organization. Similarly, the 579 repositioning of LMNA is also subtype-specific, but in this case the repositioning occurs only in non-580 metastatic cancers, although also with a high false negative rate. Interestingly, the reorganization 581 events between the different subtypes of prostate cancer appear to be gene-specific. LMNA and 582 SATB1 positioning patterns were not able to stratify prostate cancers by Gleason score and SP100, 583
TGFB3 and SATB1 were not accurate markers of risk or aggressiveness of the cancer. Consistently, 584
the radial repositioning patterns of FLI1, MMP9 and MMP2 also do not correlate with the 585 risk/aggressiveness of prostate cancer . Given that it can take many years after 586 the initial diagnosis of prostate cancer to progress to recurrence, metastasis and/or lethality This is a provisional file, not the final typeset article necessary to analyze specimens with long-term (15+ years) follow-up to accurately assess the 589 potential of spatial positioning for assessment of risk or aggressiveness. 590 591
It is unknown what mechanisms lead to the reorganization of the genome in disease, and many 592 processes have been implicated in regulating spatial positioning patterns, including changes in gene 593 expression, replication timing, chromatin modifications, altered amounts of nuclear proteins, making 594 it likely that the mis-regulations of these cellular functions in cancer cells is related to the spatial mis-595 organization of the genome (Zink et al., 2004; Meaburn, 2016; Flavahan et al., 2017) . The four genes 596
we studied have all been associated with carcinogenesis and have a range of functions. SP100 is a 597 major component of the PML nuclear body and has been implicated in transcription regulation, 598 cellular stress, oxidative stress, telomere length and stability, senescence, apoptosis and DNA 599 damage repair (Lallemand-Breitenbach and de The, 2010 2013;Naik and Galande, 2019). LMNA encodes for A-type lamins, proteins that reside predominantly 612 at the nuclear envelope, and have a variety of roles including in nuclear structure, transcription 613 regulation, and spatial genome organization (Dittmer and Misteli, 2011) . A-type lamins levels are 614 altered in many types of cancer, with reduced levels often, but not always, linked to a tendency for a 615 poorer prognostic outcome (Meaburn, 2016) . It is not currently clear what effect prostate cancer has 616 on A-type lamin protein level. On the one hand, levels of A-type lamns in prostate cancer have been 617 correlated with poor outcome, with reduced levels associated with an increased risk of lymph node 618 metastasis, and poor outcome in Gleason score 7 and higher prostate cancers (Saarinen et al., 2015) . 619
On the other hand, reduced A-type lamin levels in Gleason score 6 cancer compared to high Gleason 620 score cancer, increased A-type lamin levels in cells at the invasive leading edge of prostate cancers, 621
and enhanced migration and invasion in the presence of high A-type lamin levels have been reported 622 (Skvortsov et al., 2011; Kong et al., 2012) . 623 624
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